Safety Study of A-101 Topical Solution for the Treatment of Common Warts

Aclaris Therapeutics

Status and phase

Completed

Phase 3

Conditions

Common Wart

Treatments

Drug: A-101

Study type

Interventional

Funder types

Industry

Identifiers

NCT03812510

A-101-WART-303

Details and patient eligibility

About

A Phase 3 Study of A-101 Topical Solution Applied Twice a Week in Subjects with Common Warts

Full description

A Phase 3 Open Label Safety Study of A-101 Topical Solution for the Treatment of Common Warts

Enrollment

426 patients

Sex

All

Ages

1+ year old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject or legal guardian is able to comprehend and is willing to sign an informed consent/assent for participation in this study.
Subject must have completed study participation in either A-101-WART-301 or A-101-WART-302.
Male or female ≥ 1 years old.
Subject has a clinical diagnosis of common warts (verruca vulgaris).
Identified warts must have a longest axis of ≤8 mm

Exclusion criteria

Subject has clinically atypical warts.
Subject is immunocompromised
Subject has a history of Human Immunodeficiency Virus (HIV) infection.
Subject has had any Human Papilloma Virus (HPV) vaccine within 6 months prior to Visit 1.
Subject has used any of the following intralesional therapies within the specified period prior to Visit 1:
1. Immunotherapy (e.g., Candida antigen, mumps antigen, Trichophyton antigen); 8 weeks
2. Anti-metabolite therapy (e.g., bleomycin, 5-fluorouracil); 8 weeks
Subject has used any of the following systemic therapies within the specified period prior to Visit 1:
1. Immunomodulatory/immunosuppressant therapy (e.g., etanercept, alefacept, infliximab); 16 weeks
2. Glucocorticosteroids (inhaled and intra-nasal steroids are permitted); 28 days
Subject has used any of the following topical therapies within the specified period prior to Visit 1 on or in the proximity to any of the common warts identified for treatment that in the investigator's opinion interferes with the study medication treatment or the study assessments:
1. LASER, light or other energy-based therapy (e.g., intense pulsed light [IPL], photodynamic therapy [PDT]); 180 days
2. Immunotherapy (e.g., imiquimod, squaric acid dibutyl ester [SADBE], etc.) 12 weeks
3. Liquid nitrogen, electrodesiccation, curettage; 60 days
4. Hydrogen peroxide; 90 days (other than IP from the 301/302 study)
5. Antimetabolite therapy (e.g., 5-fluorouracil); 8 weeks
6. Retinoids; 90 days
7. Over-the-counter (OTC) wart therapies and cantharidin; 28 days
Subject currently has or has had any of the following within the specified period prior to Visit 1 on or in a proximity to any of the common warts identified for treatment that, in the investigator's opinion, interferes with the study medication treatment or the study assessments:
1. Cutaneous malignancy; 180 days
2. Sunburn; currently
3. Pre-malignancy (e.g., actinic keratosis); currently
Subject has a history of sensitivity to any of the ingredients in the study medications.
Subject has any current skin or systemic disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage), or condition (e.g., sunburn, excessive hair, open wounds) that, in the opinion of the investigator, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations.
Participation in another therapeutic investigational drug/device trial (other than the Aclaris 301 or 302 study) in which administration of an investigational treatment occurred within 30 days prior to Visit 1.
Subject has an active malignancy.